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ABSTRACT
Severe falciparum malaria remains a common cause of death among the under-5 Nigerian children despite Nigerians having partial immunity arising 
from their residence in a hyperendemic region for malaria transmission. It is, also, being reported in clinical practice among adolescent and adult 
Nigerians. The objective of this narrative review is to highlight the pathophysiology of severe malaria and relate that to its clinical manifestations/
complications and to highlight the challenges of severe malaria management in Nigeria. With a good understanding of the pathophysiology of severe 
malaria as it relates to its clinical manifestations, one expects a favorable outcome from the current treatment protocol.
Keywords: Severe falciparum malaria, Pathophysiology and clinical manifestations of severe malaria, Nigeria, Management challenges of severe 
malaria.
INTRODUCTION
Malaria in man is an infection caused by any of the following malarial 
parasites of the plasmodium species – Plasmodium falciparum, 
Plasmodium malariae, Plasmodium vivax, and Plasmodium ovale – which 
are spread to people through the bites of infected female Anopheles 
mosquitoes. P. falciparum is the most common of the parasites in 
most of the sub-Saharan Africa where it accounts for almost all the 
mortalities [1]. The global malaria burden is disproportionately borne 
by sub-Saharan Africa such that in 2015, the region had 90% of the 
global malaria cases and 92% of the malarial deaths [2].
Malaria can be severe or uncomplicated. According to the World Health 
Organization (WHO) [3], the criteria for severe malaria include that 
the malaria must be attributable to P. falciparum, the patient with the 
malaria is unable to swallow tablets, has evidence of, at least, one vital 
organ dysfunction or has a high malaria parasite count in his/her blood, 
and is at increased risk of dying. Additional WHO criteria [3] for the 
diagnosis of severe malaria from 2000 include impaired consciousness, 
prostration or general body weakness, hyperparasitemia (>5% 
parasitized erythrocytes), hyperpyrexia (core body temperature 
>40°C), and hyperbilirubinemia (total bilirubin >2.5 mg/dl). Severe 
malaria is a potentially fatal but treatable disease.
As regard to the risk of severe malaria [3], it has been shown that in 
parts of the world where malaria is endemic, transmission of falciparum 
malaria is stable such that severe malaria is mainly a disease of children 
from the first few months of life to the age of 5 years. It is less common 
in older children and adults in those regions because they have partial 
immunity. In their study in Jos [4], Nigeria, 71% of the children admitted 
for severe malaria were aged 5 years and below. Mortality in that study 
was associated with hypoglycemia, severe anemia, shock, and repeated 
prolonged seizures. Similarly, in their study in Enugu [5], Nigeria, 66.7% 
of the children treated for severe malaria were under the age of 5 years 
with 8.8% of them being 6 months and below. In areas of the world with 
lower endemicity, severe malaria occurs in both children and adults. 
Travelers and migrant workers who do not have malaria immunity are 
at increased risk for severe malaria.
In some other studies, risk factors for severe malaria and death noted 
included age >65 years, female sex (especially when associated with 
pregnancy), non-immune status, coexisting medical conditions, no 
Severe malaria is a major cause of death among children and often the 
major reason for children hospital admissions in sub-Saharan Africa. 
In Nigeria, malaria is one of the most important health problems [9], 
accounting for 25% of infant mortality, 30% of under-5 mortality, and 
11% of maternal mortality. Severe malaria is a medical emergency 
that is rapidly associated with complications and death if prompt and 
appropriate treatment is not given.
PATHOPHYSIOLOGY OF SEVERE MALARIA
P. falciparum [10] attacks red blood cells (RBCs) at all stages of 
development unlike P. malaria which preferentially attacks old RBCs or P. 
ovale and P. vivax which prefer to attack reticulocytes (developing RBCs). 
In severe malaria, there is heavy parasitemia, in which the proportion of 
parasitized RBCs increases to more than 3% of the total RBCs.
The heavy load of P. falciparum in the peripheral blood [10] consumes 
and degrades the hemoglobin in the RBCs, the RBCs become irregular 
in shape, less deformable, adhere to venule and capillary endothelium 
to form cytoadherence, adhere to uninfected RBCs to form rosettes, 
and to other parasitized RBCs to form agglutination. Consumption and 
degradation of the RBCs hemoglobin, hemolysis of parasitized RBCs, 
blackwater fever, hypersplenism, and nutrients deficiency all lead to 
the severe anemia in complicated malaria. With massive hemolysis, lots 
of hemoglobin are liberated into the peripheral blood, are filtered in the 
renal glomeruli to cause hemoglobinuria.
The process of cytoadherence, rosetting, and agglutination is central to 
severe malaria pathogenesis [10]. Reduced deformability of the RBCs 
(parasitized) compromises their passage through the microcirculation 
resulting in reduced RBCs survival or lifespan, causes ischemic 
changes in the affected organs/tissues such that ensuing peripheral 
vasodilatation which occurs in an attempt to correct ischemia leads to 
systemic hypotension (shock). Shock in severe malaria could, also, be 
from sepsis which is a common associated feature of severe malaria.
With shock, anaerobic glycolysis occurs at the cellular level resulting to 
increased production of lactic acid, thus, leading to increased anion gap 
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antimalarial prophylaxis, delay in treatment, and severity of the illness 
at admission (coma, acute kidney injury [AKI], shock, 
pulmonary edema, or coagulation disorders) [6-8].
metabolic acidosis. Metabolic acidosis and hypoglycemia remain the 
main metabolic complications of severe malaria.
Exoerythrocytic phase of P. falciparum infection (in liver) causes 
decreased hepatic gluconeogenesis, leading to hypoglycemia. 
Other causes of hypoglycemia in severe malaria include increased 
consumption of glucose by the falciparum parasites in RBCs and the 
increased pancreatic beta-cells stimulation by quinine and quinidine 
used in treating severe (complicated) malaria.
Microcirculation in the glomeruli of the kidneys is compromised by 
the processes of cytoadherence, rosetting, and agglutination resulting 
to pre-renal acute kidney failure which presents with oliguria and 
azotemia. Free hemoglobin filtered in the renal glomeruli, may, also, add 
to the AKI. Similarly, cerebral microcirculation is compromised, leading 
to ischemic changes and cerebral edema which manifest as confusion, 
convulsion, and coma seen in cerebral malaria.
Acute respiratory distress syndrome/acute pulmonary edema in severe 
malaria results from the hyperparasitemia itself, overhydration in the 
process of treating severe malaria, acute renal failure, and pregnancy. 
Hyperpyrexia in severe malaria is a consequence of cytokines and other 
pyrogens from lysed RBCs.
CLINICAL FEATURES/COMPLICATIONS OF SEVERE MALARIA
The major complications of severe malaria include cerebral malaria, 
acute renal failure, metabolic acidosis, hypoglycemia, acute respiratory 
distress syndrome/pulmonary edema, severe anemia, and/or bleeding. 
Any of these complications, once developed, can progress rapidly to 
death within hours to days and the complications can exist together or 
start within a few hours of the onset of another complication[3]. In no 
particular order, the complications in patients with severe malaria are 
discussed below.
Cerebral malaria
This is the most common clinical presentation of severe malaria as well 
as the most common cause of death in patients with severe malaria. 
In view of the aforementioned, some practitioners erroneously believe 
that cerebral malaria is synonymous with severe malaria. Cerebral 
malaria presents with confusion, drowsiness, and progressing to 
generalized convulsion and coma. Delirium, agitation, and even 
transient paranoid psychosis may develop as the patient recovers 
consciousness.
Cerebral malaria [11] is defined as the presence of P. falciparum 
parasitemia, in which the patient is unconscious with a Glasgow Coma 
Scale (GCS) score of 9 or less and other causes (e.g., hypoglycemia, 
bacterial meningitis, and viral encephalitis) are ruled out. Neck stiffness 
and focal neurologic deficits are absent and there is no specific EEG 
changes characteristic of severe malaria, but computed tomography 
and magnetic resonance imaging often show evidence of diffuse mild 
cerebral edema. Mortality of cerebral malaria ranges from 10% to 
50% with treatment and most survivors have no neurologic deficits on 
discharge from hospitals [11].
Pulmonary complications
The first indication of impending pulmonary edema is breathlessness, 
followed by hypoxemia and Type 1 respiratory failure which may 
require intubation and mechanical ventilation. Pulmonary edema 
presents with O2 saturation <92% on room air and a respiratory 
rate >30/min and can be confirmed radiologically from a chest 
radiograph. Acute lung injury usually occurs few days after onset 
of severe malaria. Pulmonary edema in severe malaria is usually 
non-cardiogenic (no evidence of the left atrial hypertension) and 
may progress to acute respiratory distress syndrome with an 
increased pulmonary capillary permeability [12]. Volume overload 
in the course of intravenous (i.v) fluid administration can worsen 
pulmonary capillary leakage. Acute pulmonary edema rarely is seen 
with P. vivax and P. ovale malaria.
Acute renal failure
In severe malaria, AKI [13] usually presents with oliguria (urine 
volume <400 ml in 24 h) or anuria (urine volume <50 ml in 24 h) 
and azotemia (plasma creatinine is >265 µmol/l [3 mg/dl] and blood 
urea >20 mmol/l). It is worth noting that hemoglobinuria resulting 
from massive intravascular hemolysis which manifests as the passage 
of dark red, brown, or black urine is transient and not a cause of AKI. 
This passage of dark-colored urine arising from massive intravascular 
hemolysis is called blackwater fever.
Hypotension and shock
This is usually associated with postural hypotension due to autonomic 
dysfunction. In the setting of severe malaria, cardiac pump function is 
usually preserved. Severe hypotension can be from pulmonary edema, 
metabolic acidosis, sepsis, and/or massive hemorrhage due to splenic 
rupture or bleeding into the gastrointestinal tract [13].
Hypoglycemia
This is a common feature of severe malaria which may be overlooked 
or missed because the clinical features of hypoglycemia (anxiety, 
breathlessness, tachycardia, sweating, coma generalized convulsions, 
etc.) are typical features of severe malaria per se. Hypoglycemia may 
be caused by quinine or quinidine which acts on the beta-cells of the 
pancreas to induce hyperinsulinemia [10].
Severe malarial anemia
Severe anemia is a common complication in the setting of severe malaria. 
In this regard, hemoglobin concentration is <5 gm/dl or hematocrit 
is <15% in children <12 years and in older children (>12 years) and 
adults, a hemoglobin concentration of <7gm/dl or hematocrit <20% 
defines severe anemia [14].
Significant bleeding
Some patients with severe malaria may present with recurrent or 
prolonged bleeding from the nose, gum, and venipuncture sites while 
some present with hematemesis or melena.
MANAGEMENT OF SEVERE MALARIA
Components of the management of severe malaria include clearance of 
the malarial parasites with specific antimalarial agents, diagnosis, and 
management of associated complications of severe malaria, additional 
treatment, and supportive care of the patient. The management of 
severe malaria begins with clinical assessment of the patient.
Clinical assessments
All patients with a diagnosis of severe malaria must be admitted in 
a hospital ward, preferably in an intensive care unit (ICU) setting if 
the facilities are available. If unconscious, the GCS score is determined 
at presentation and monitored regularly, an open airway is secured, 
breathing and circulation are assessed. Each patient being admitted 
for severe malaria is weighed or body weight is estimated for the 
purpose of antimalarial drug doses and fluids requirement. Thereafter, 
an i.v cannula is inserted for fluids administration and blood samples 
are collected for random blood glucose, serum electrolytes, urea and 
creatinine for renal function, hemoglobin concentration, blood film for 
malarial parasites, full blood count, venous lactate, arterial blood pH 
and gases, grouping and cross=matching a few pints of blood, clotting 
studies, platelet count, and blood culture for bacteria. Patient should, 
also, be assessed for fluid balance to avoid over- or underhydration. 
Cerebral malaria is not associated with signs of meningeal irritation 
such as neck stiffness, photophobia, or positive Kernig’s sign.
It is important to note that in severe malaria, septicemia, pneumonia, 
and severe malaria may coexist [14]. There is a considerable clinical 
overlap between them such that in all cases of severe malaria, blood 
culture for bacteria is indicated. For the same reason, empirical 
parenteral broad-spectrum antibiotics should be started immediately 
with antimalarial treatment [14].
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Specific antimalarial treatment
Parenteral antimalarial agents must be used in all cases of severe 
malaria. This should be followed by a full dose of effective artemisinin-
based combination therapy (ACT) orally. The two classes of drugs which 
are indicated in severe malaria are artemisinin derivatives (artesunate 
or artemether) and the Cinchona alkaloids [14] (quinine or quinidine).
Parenteral artesunate is the treatment of choice [14] and should be 
given to all adults and children (including infants, pregnant women in 
all trimesters, and lactating women) with a diagnosis of severe malaria 
through i.v or intramuscular routes for at least 24 h. Once a patient has 
received, at least 24 h of parenteral artesunate and can tolerate oral 
therapy, treatment is completed with an ACT for 3 days.
Children weighing <20 kg should receive 3 mg/kg body weight/dose 
of artesunate while bigger children (weighing >20 kg) and adults 
should receive 2.4 mg/kg body weight/dose of artesunate. Artesunate 
is dispensed as a powder of artesunic acid which is dissolved in 5% 
sodium bicarbonate to form sodium artesunate. The latter is diluted 
in 5 ml 5% dextrose and given i.v or intramuscular into the anterior 
thigh. Freshly prepared sodium artesunate is preferred and should not 
be stored for future use.
It is important to note that if artesunate is not available, intramuscular 
artemether is preferred to quinine for treating children and adults with 
severe malaria [14]. It is administered at a loading dose of 3.2 mg/kg 
body weight at presentation and 1.6 mg/kg body weight daily for the 
subsequent 5 days.
Quinine dihydrochloride is the most widely used of the quinine salts 
indicated in severe malaria. Quinine gluconate is less painful than 
quinine dihydrochloride when given by intramuscular injection 
while the sulfate is for oral administration. Quinine dihydrochloride 
is started with a loading dose of 20 mg salt/kg body weight with a 
maintenance dose of 10 mg/kg body weight given 8 hourly starting 8 h 
after the loading dose. If there is no improvement after 48 h on quinine, 
the dose is reduced to 10 mg/kg body weight every 12 h. Each dose 
of quinine should be given as a slow rate controlled infusion (in 5% 
dextrose water or saline) infused over 4 h. If i.v infusion of quinine 
is not possible, it should be given by intramuscular injection to the 
anterior thigh; it should not be injected into the buttocks to avoid injury 
to the sciatic nerve. Note that, rapid i.v administration of quinine is 
dangerous and quinine is never given by i.v bolus injection as it causes 
fatal hypotension. Overdose of quinine is associated with deafness and 
blindness.
Additional treatment and supportive care
After a minimum of 24 h on parenteral antimalarial agent and once 
patient can tolerate oral drugs, the patient should be started on 
an effective ACT medication (such as artesunate+amodiaquine, 
dihydroartemisinin+piperaquine, or artemether+lumefantrine). 
ACTs containing mefloquine are avoided if patient presented with 
unconsciousness due to the risk of neuropsychiatric complications. 
Non-ACT-based combination regimen such as quinine+clindamycin 
or quinine+doxycycline can be used as additional treatment after 
parenteral antimalaria. Doxycycline is not given to children (<8 years) 
and pregnant women.
Intensive nursing care as well as effective monitoring of vital signs, GCS 
score, blood glucose, and urine output are crucial in the management 
of severe malaria.
Management of complications of severe malaria
Diagnosis of the associated complications should be promptly made 
and treatment [14] commenced as follows at the same time that the 
parenteral antimalarial agents are given:
1. Severe malarial anemia – is treated by transfusion with screened 
fresh blood
2.	 Hypoglycemia	–	confirm	by	checking	random	blood	glucose;	correct	
and maintain normal blood glucose with dextrose infusion
4. Cerebral malaria (and unconsciousness) – maintain airway, lie patient 
on his/her side, exclude other causes of coma such as hypoglycemia 
and bacterial meningitis. Control convulsion with i.v or rectal 
diazepam, lorazepam, midazolam, or intramuscular paraldehyde
6. Shock – sepsis may be the cause; therefore, take blood for 
bacterial	culture	and	sensitivity,	give	fluid	to	correct	hemodynamic	
disturbances, and administer broad-spectrum antibiotics for sepsis
ice-cold sponging, fanning, and use of cooling blanket.
CHALLENGES IN THE MANAGEMENT OF SEVERE MALARIA IN 
NIGERIA
Being in an endemic region for malarial transmission, severe malaria 
in Nigeria is seen mostly in children aged <5 years. This vulnerable 
age group is very dependent on the parent’s health-seeking behavior 
to decide where and when to seek medical care when these children 
have a febrile illness. Some parents could equally decide not to seek 
any medical attention for their ill children. With the level of poverty in 
Nigeria, illiteracy, lack of effective health insurance scheme, and out-
of-pocket payment for medical services, patients with severe malaria 
present initially to medically unqualified health workers who often 
fail to make the correct diagnosis and undertreat the patients. By the 
time, the patients present to the qualified health-care professionals, 
they are moribund and in worse clinical states. Late presentation to the 
pediatrician at a time when the clinical features may have deteriorated 
so much creates difficulties with accurate diagnosis of severe malaria 
and its complications.
Second, ICU facilities in most tertiary hospitals in Nigeria are grossly 
inadequate to care for severe malaria and other critical medical, 
surgical, and obstetric conditions. These ICU facilities are practically 
not available in the primary and secondary health facilities in Nigeria 
where most children with severe malaria present initially.
Another major challenge to the successful management of severe 
malaria in Nigeria is the quality of antimalarial agents in the markets. 
A lot of low quality and substandard antimalarial agents imported 
by profit-motivated traders are in circulation and these are used 
unknowingly for treating cases of severe malaria. With this, the outcome 
of severe malaria treatment in Nigeria has remained poor.
Again, the workforce adequacy of Nigeria to deal with the problems of 
severe malaria is far from being enough. The pediatricians work mainly 
in the tertiary health facilities located in the cities while the health 
facilities in the hinterlands are manned by healthcare workers (doctors 
and nurses) who, most times, are not skilled and experienced enough to 
deal with severe malaria and its complications.
Finally, the laboratory support services needed to make accurate 
diagnosis of severe malaria and its complications are grossly lacking in 
the rural areas of Nigeria. Blood transfusion services are inadequate and 
the turnaround time for obtaining certain essential laboratory results 
(such as urea, creatinine, and lactate) is still more than 48 h. Dialysis 
services are available, especially at the cities but are not affordable to 
all the patients.
CONCLUSION
Severe malaria is a potentially fatal medical emergency. In Nigeria, 
severe malaria still contributes significantly to childhood mortality. 
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7. Spontaneous bleeding – transfuse with fresh whole blood
8. Metabolic acidosis – may require hemodialysis
9. Hyperpyrexia – use of antipyretic agent (e.g., parenteral paracetamol), 
3. Acute pulmonary edema – patient is nursed propped up at 45°, 
oxygen	is	given,	loop	diuretic	is	administered,	and	i.v	fluids	stopped.	
If need be (life-threatening hypoxemia), patient is intubated and 
positive pressure ventilation is given
5.	 AKI	–	if	patient	has	pre-renal	AKI,	 fluid	challenge	may	be	helpful.	
Hemofiltration	or	hemodialysis	 is	 indicated	 in	established	acute	
renal failure
With a good grasp of the pathophysiology of severe malaria and how 
the complications arise, the health-care professionals should be in 
a position to offer treatment that will be associated with favorable 
outcome. The challenges to the successful management of severe 
malaria in Nigeria are enormous but with the right government policy, 
good health funding, and capacity building, morbidity and mortality 
from severe malaria in Nigeria can be considerably reduced.
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